IN2014MN00139A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN00139A IN2014MN00139A IN139MUN2014A IN2014MN00139A IN 2014MN00139 A IN2014MN00139 A IN 2014MN00139A IN 139MUN2014 A IN139MUN2014 A IN 139MUN2014A IN 2014MN00139 A IN2014MN00139 A IN 2014MN00139A
- Authority
- IN
- India
- Prior art keywords
- endoxifen
- formulations
- diseases
- breast
- agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86042006P | 2006-11-21 | 2006-11-21 | |
| US86078806P | 2006-11-22 | 2006-11-22 | |
| PCT/US2007/085443 WO2008070463A2 (en) | 2006-11-21 | 2007-11-21 | Endoxifen methods and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN00139A true IN2014MN00139A (ar) | 2015-06-19 |
Family
ID=39492975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN139MUN2014 IN2014MN00139A (ar) | 2006-11-21 | 2007-11-21 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9333190B2 (ar) |
| EP (1) | EP2101731B1 (ar) |
| JP (1) | JP2010510327A (ar) |
| CA (1) | CA2669913C (ar) |
| DK (1) | DK2101731T3 (ar) |
| ES (1) | ES2665917T3 (ar) |
| HU (1) | HUE037109T2 (ar) |
| IN (1) | IN2014MN00139A (ar) |
| PL (1) | PL2101731T3 (ar) |
| PT (1) | PT2101731T (ar) |
| WO (1) | WO2008070463A2 (ar) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014MN00139A (ar) | 2006-11-21 | 2015-06-19 | Jina Pharmaceuticals Inc | |
| US20090291134A1 (en) * | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
| SI2373305T1 (sl) * | 2008-12-11 | 2017-09-29 | Besins Healthcare Luxembourg Sarl | Transdermalni farmacevtski sestavki, ki obsegajo serm |
| RS56462B1 (sr) | 2011-04-28 | 2018-01-31 | Oncopeptides Ab | Liofilizovani preparat citotoksičnih dipeptida |
| EP2668945A1 (de) | 2012-06-01 | 2013-12-04 | Bayer Technology Services GmbH | Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen |
| AU2013335359B2 (en) * | 2012-10-26 | 2016-07-21 | Oncopeptides Innovation Ab | Lyophilized preparations of melphalan flufenamide |
| CN108024959A (zh) * | 2015-07-14 | 2018-05-11 | 阿托萨遗传学公司 | 用于治疗乳腺病症的经乳头方法和组合物 |
| DE102015222031A1 (de) | 2015-11-10 | 2017-05-11 | Robert Bosch Gesellschaft Für Medizinische Forschung Mbh | Synthese von (Z)-Endoxifenhydrochlorid |
| US20170304232A1 (en) * | 2016-04-20 | 2017-10-26 | Northwestern University | Endoxifen For Local Transdermal Therapy To The Breast |
| TWI793165B (zh) | 2017-09-11 | 2023-02-21 | 美商阿托薩醫療公司 | 製造及使用因多昔芬(endoxifen)之方法 |
| SG11202001885WA (en) * | 2017-09-11 | 2020-03-30 | Atossa Therapeutics Inc | Topical compositions and methods for treatment |
| JP2022538911A (ja) * | 2019-07-03 | 2022-09-06 | アトッサ・セラピューティクス・インコーポレイテッド | エンドキシフェンの徐放性組成物 |
| WO2021205402A1 (en) | 2020-04-10 | 2021-10-14 | Jina Pharmaceuticals, Inc. | Endoxifen for the treatment of bipolar i disorder |
| WO2022197988A1 (en) * | 2021-03-18 | 2022-09-22 | National Taiwan University | Lipid-based nanoparticle delivery system for hydrophilic charged compound |
| TW202340135A (zh) | 2022-01-12 | 2023-10-16 | 美商阿托薩醫療公司 | （ｚ）—因多昔芬之組合物及其富集方法 |
| WO2023211939A1 (en) * | 2022-04-26 | 2023-11-02 | Atossa Therapeutics, Inc. | High dose endoxifen formulations and methods of use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2817157A1 (de) * | 1978-04-17 | 1979-10-25 | Schering Ag | Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie |
| US6290991B1 (en) * | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| NZ290896A (en) * | 1994-08-04 | 1997-04-24 | Quadrant Holdings Cambridge | Solid dose delivery composition containing a glassy vehicle and at least one guest substance |
| JP2001507207A (ja) * | 1996-05-01 | 2001-06-05 | イマアーレクス・フアーマシユーチカル・コーポレーシヨン | 化合物を細胞に送達する方法 |
| US6090407A (en) * | 1997-09-23 | 2000-07-18 | Research Development Foundation | Small particle liposome aerosols for delivery of anti-cancer drugs |
| US7968532B2 (en) | 2003-12-15 | 2011-06-28 | Besins Healthcare Luxembourg | Treatment of gynecomastia with 4-hydroxy tamoxifen |
| PT2076244T (pt) | 2006-10-10 | 2017-03-09 | Jina Pharmaceuticals Inc | Sistemas aquosos para a preparação de compostos farmacêuticos à base de lípidos; composições, métodos e utilizações dos mesmos |
| WO2008048194A1 (en) | 2006-10-20 | 2008-04-24 | Yesilogluj Aysegul Yildiz | Use of the protein kinase c inhibitor tamoxifen for the treatment of bipolar disorder |
| WO2008058156A2 (en) | 2006-11-06 | 2008-05-15 | Jina Pharmaceuticals Inc. | Guggulphospholipid methods and compositions |
| US20090291134A1 (en) * | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
| IN2014MN00139A (ar) | 2006-11-21 | 2015-06-19 | Jina Pharmaceuticals Inc | |
| JP5720881B2 (ja) | 2011-01-31 | 2015-05-20 | 東芝ライテック株式会社 | Ｌｅｄランプ点灯装置および照明装置 |
-
2007
- 2007-11-21 IN IN139MUN2014 patent/IN2014MN00139A/en unknown
- 2007-11-21 US US12/515,261 patent/US9333190B2/en active Active
- 2007-11-21 PT PT78715638T patent/PT2101731T/pt unknown
- 2007-11-21 HU HUE07871563A patent/HUE037109T2/hu unknown
- 2007-11-21 WO PCT/US2007/085443 patent/WO2008070463A2/en active Application Filing
- 2007-11-21 PL PL07871563T patent/PL2101731T3/pl unknown
- 2007-11-21 ES ES07871563.8T patent/ES2665917T3/es active Active
- 2007-11-21 CA CA2669913A patent/CA2669913C/en active Active
- 2007-11-21 EP EP07871563.8A patent/EP2101731B1/en not_active Revoked
- 2007-11-21 DK DK07871563.8T patent/DK2101731T3/en active
- 2007-11-21 JP JP2009538518A patent/JP2010510327A/ja active Pending
-
2016
- 2016-04-27 US US15/139,687 patent/US10376479B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2669913C (en) | 2012-09-18 |
| WO2008070463A3 (en) | 2008-11-06 |
| PT2101731T (pt) | 2018-04-18 |
| US10376479B2 (en) | 2019-08-13 |
| EP2101731A2 (en) | 2009-09-23 |
| ES2665917T3 (es) | 2018-04-30 |
| CA2669913A1 (en) | 2008-06-12 |
| EP2101731B1 (en) | 2018-01-31 |
| US20160346230A1 (en) | 2016-12-01 |
| WO2008070463A9 (en) | 2008-09-18 |
| US20100112041A1 (en) | 2010-05-06 |
| JP2010510327A (ja) | 2010-04-02 |
| WO2008070463A2 (en) | 2008-06-12 |
| PL2101731T3 (pl) | 2018-07-31 |
| DK2101731T3 (en) | 2018-04-16 |
| EP2101731A4 (en) | 2011-04-20 |
| HUE037109T2 (hu) | 2018-08-28 |
| US9333190B2 (en) | 2016-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN00139A (ar) | ||
| MY155649A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| EA201690265A2 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| PH12014501560A1 (en) | Carbamate compounds and of making and using same | |
| MX2010014233A (es) | Compuestos quimicos 251. | |
| UA107783C2 (en) | Isoindoline compounds for use in treating cancer | |
| TN2012000143A1 (en) | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof | |
| AU2011338389A8 (en) | Bicyclic compounds as Pim inhibitors | |
| MX2008011978A (es) | Tratamiento del cancer de seno negativo al triple receptor. | |
| MY198422A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| MX2007002398A (es) | Nuevas composiciones farmaceuticas para el tratamiento de cancer. | |
| MX337575B (es) | Compuestos de sulfona y métodos para lafabricación y uso de éstos. | |
| IL206563A (en) | A preparation or drug containing a suspension of blood cells that contain asparaginase for use in the treatment of pancreatic cancer | |
| TNSN07093A1 (en) | Bicyclic amides as kinase inhibitors | |
| MX2009006704A (es) | Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. | |
| UA86614C2 (ru) | Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата | |
| MY179527A (en) | Catecholamine derivatives useful for the treatment of parkinson's disease | |
| UA104988C2 (uk) | Похідні піроніндолу та спосіб їх отримання | |
| TW200628473A (en) | Novel heterocycles | |
| WO2007121088A3 (en) | Combinations of therapeutic agents for treating cancer | |
| MX2009006327A (es) | Compuestos heterociclicos y metodos de uso de los mismos. | |
| GB0620385D0 (en) | Novel compounds | |
| EA201291089A1 (ru) | Способ получения фармацевтических препаратов, предназначенных для перорального введения, содержащих один или более активных ингредиентов, и содержащих их композиций | |
| GEP201606513B (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
| PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor |